CMPS
COMPASS Pathways plcNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-10.26
P/S
0.00
EV/EBITDA
-1.87
DCF Value
$1.38
FCF Yield
-28.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-335.9%
ROA
-136.8%
ROIC
996.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-93.9M | $-1.00 |
| FY 2025 | $0.00 | $-287.9M | $-3.08 |
| Q3 2025 | $0.00 | $-137.7M | $-1.44 |
| Q2 2025 | $0.00 | $-38.4M | $-0.41 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
GB
Exchange
NASDAQ
Beta
2.02
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.